GEMSA

Cat. No.:	HY-118120
CAS No.:	77482-44-1
Molecular Formula:	$C_7H_{13}N_3O_4S$
Molecular Weight:	235.26
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	GEMSA is a potent inhibitor of enkephalin convertase (K_i=8.8 nM). GEMSA elicites analgesia[1].
IC_{50} & Target	Encephalin convertase, K_i ⊠⊠8.8 nM.
In Vitro	GEMSA inhibits the activation of TAFI and porcine CBB[1]. GEMSA can inhibit the prolongation of lysis time in recombinant BAP and does not lead to the lysis of APC fibronectin[1]. GEMSA inhibits the prolongation of lysis time in porcine CPB, TAFI, and recombinant BAP, APC with the EC_{50} values of 0.34 μM, 100μM, 115 μM, 90 μM respectively[1][2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	GEMSA (ICV, 0.1μg/mg, every, 3days) results in a 75% increase in hypothalamic luteinizing hormone-releasing hormone and serum luteinizing hormone levels, and a 60% decrease in serum prolactin concentrations in rat[3] MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. B Przewlocka, et al. Analgesic and convulsant effects of guanidinoethylmercaptosuccinic acid (GEMSA)--a potent enkephalin convertase inhibitor. Neuropeptides. Nov-Dec 1986;8(4):359-65.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA